Abstract
The recent introduction of four biosimilars to the anti‐TNF monoclonal antibody adalimumab has raised the prospect of significant cost savings for the NHS. But what are biosimilar medicines, how easy is it to switch patients and how likely is it that large savings will be possible?
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
